Item response theory analysis and properties of decisional conflict scales: findings from two multi-site trials of men with localized prostate cancer

by Rachel A. Pozzar, Donna L. Berry, Fangxin Hong
Published 2019-07-01

Exploring the impact of a decision support algorithm to improve clinicians’ chemotherapy-induced peripheral neuropathy assessment and management practices: a two-phase, longitudina...

by Robert Knoerl, Emanuele Mazzola, Fangxin Hong, Elahe Salehi, Nadine McCleary, Jennifer Ligibel, Kaitlen Reyes, Donna L. Berry
Published 2021-03-01

Measurement properties of brief neuropathy screening items in cancer patients receiving taxanes, platinums, or proteasome inhibitors

by Robert Knoerl, Emanuele Mazzola, Sandra A. Mitchell, Fangxin Hong, Elahe Salehi, Nadine McCleary, Jennifer A. Ligibel, Kaitlen Reyes, Donna L. Berry
Published 2021-09-01

Correction: MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy

by Mehmet Altan, Fangxin Hong, John V Heymach, Elizabeth Jiménez-Aguilar, Zihan Wei, Andrew J Plodkowski, Peter Sawan, Jia Luo, Hira Rizvi, Brett W Carter
Published 2020-07-01

Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status

by Mehmet Altan, Fangxin Hong, John V Heymach, Elizabeth Jiménez-Aguilar, Zihan Wei, Andrew J Plodkowski, Peter Sawan, Jia Luo, Hira Rizvi, Brett W Carter
Published 2020-07-01

Assigning value to preparation for prostate cancer decision making: a willingness to pay analysis

by Leslie S. Wilson, Traci M. Blonquist, Fangxin Hong, Barbara Halpenny, Seth Wolpin, Peter Chang, Christopher P. Filson, Viraj A. Master, Martin G. Sanda, Gary W. Chien, Randy A. Jones, Tracey L. Krupski, Donna L. Berry
Published 2019-01-01

Network discovery pipeline elucidates conserved time-of-day-specific cis-regulatory modules.

by Todd P Michael, Todd C Mockler, Ghislain Breton, Connor McEntee, Amanda Byer, Jonathan D Trout, Samuel P Hazen, Rongkun Shen, Henry D Priest, Christopher M Sullivan, Scott A Givan, Marcelo Yanovsky, Fangxin Hong, Steve A Kay, Joanne Chory
Published 2008-02-01

Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab

by Amy K. Erbe, Wei Wang, Lakeesha Carmichael, Anna Hoefges, Bartosz Grzywacz, Patrick K. Reville, Erik A. Ranheim, Jacquelyn A. Hank, KyungMann Kim, Songwon Seo, Eneida A. Mendonca, Yiqiang Song, Vaishalee P. Kenkre, Fangxin Hong, Randy D. Gascoyne, Elisabeth Paietta, Sandra J. Horning, Jeffrey S. Miller, Brad Kahl, Paul M. Sondel
Published 2019-03-01

HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy

by Amy K. Erbe, Wei Wang, Patrick K. Reville, Lakeesha Carmichael, KyungMann Kim, Eneida A. Mendonca, Yiqiang Song, Jacquelyn A. Hank, Wendy B. London, Arlene Naranjo, Fangxin Hong, Michael D. Hogarty, John M. Maris, Julie R. Park, Julie R. Park, M. F. Ozkaynak, Jeffrey S. Miller, Andrew L. Gilman, Brad Kahl, Alice L. Yu, Alice L. Yu, Paul M. Sondel, Paul M. Sondel
Published 2017-06-01

SPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA Genotyping

by Marissa N. Lawrence, BS, Rubii M. Tamen, BA, Pablo Martinez, MD, PhD, Alicia Sable-Hunt, RN, MBA, CCRA, Tony Addario, Pete Barbour, MS, MPM, PMP, Tristan Shaffer, BS, Seyed Ali Hosseini, MD, PhD, Caterina Bertucci, BS, MPA, Lee P. Lim, PhD, Fangxin Hong, PhD, Kesi Michael, BS, George R. Simon, MD, Jonathan W. Riess, MD, PhD, Mark M. Awad, MD, PhD, Geoffrey R. Oxnard, MD
Published 2021-04-01